Desmopressin - Ferring Pharmaceuticals

Drug Profile

Desmopressin - Ferring Pharmaceuticals

Alternative Names: DDAVP; MINIRIN

Latest Information Update: 29 Oct 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ferring Pharmaceuticals
  • Class Antidiuretics; Antihaemorrhagics; Hormones; Urologics; Vasoconstrictors; Vasopressins
  • Mechanism of Action Vasopressin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diabetes insipidus; Enuresis

Most Recent Events

  • 22 Oct 2014 Launched for Diabetes insipidus and Enuresis in World (Intranasal, IV, PO, SCl) prior to October 2014
  • 22 Oct 2014 Ferring Pharmaceuticals acquires rights to desmopressin from Sanofi
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top